| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,677 |
6,454 |
$582K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,338 |
3,518 |
$217K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,829 |
1,591 |
$210K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,607 |
1,411 |
$125K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
9,763 |
4,204 |
$88K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,625 |
3,383 |
$87K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,215 |
1,646 |
$41K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,201 |
2,884 |
$36K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,559 |
3,016 |
$31K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,706 |
2,293 |
$29K |
| 87428 |
|
458 |
431 |
$19K |
| 71046 |
Radiologic examination, chest; 2 views |
816 |
687 |
$12K |
| 87807 |
|
918 |
754 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
300 |
257 |
$7K |
| 81002 |
|
1,176 |
1,060 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,368 |
1,183 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
50 |
46 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
219 |
199 |
$2K |
| 81025 |
|
655 |
580 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
661 |
583 |
$731.97 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,855 |
1,612 |
$713.72 |
| 81003 |
|
99 |
49 |
$87.00 |
| 36415 |
Collection of venous blood by venipuncture |
39 |
37 |
$64.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
17 |
17 |
$19.84 |
| 1170F |
|
2,701 |
2,397 |
$1.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
104 |
95 |
$0.09 |
| 1159F |
|
2,506 |
2,239 |
$0.00 |
| 1494F |
|
1,095 |
969 |
$0.00 |
| 3078F |
|
888 |
826 |
$0.00 |
| 1160F |
|
2,505 |
2,237 |
$0.00 |
| 3077F |
|
304 |
282 |
$0.00 |
| G8421 |
Bmi not documented and no reason is given |
16 |
13 |
$0.00 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
40 |
37 |
$0.00 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
146 |
138 |
$0.00 |
| 3008F |
|
3,206 |
2,801 |
$0.00 |
| 2010F |
|
243 |
221 |
$0.00 |
| 3079F |
|
318 |
298 |
$0.00 |
| 3074F |
|
1,029 |
962 |
$0.00 |
| 1125F |
|
13 |
13 |
$0.00 |
| 2001F |
|
385 |
346 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
358 |
324 |
$0.00 |
| 3075F |
|
196 |
182 |
$0.00 |
| 3080F |
|
212 |
198 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
65 |
61 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
209 |
86 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
93 |
88 |
$0.00 |